Replies to post #100528 on Biotech Values

[DewDiligence]

The prevalence of the EML4-ALK fusion oncogene is higher among lung adenocarcinomas, in non or light smokers, and in EGFR, KRAS-negative cases.

Are there significant commercial ramifications associated with this observation (apart from the raw frequency of the variant)? T.i.a.

[poorgradstudent]

ARIA's ALK inhibitor is apparently slated for IND in mid-2011.

Pretty disappointing from my point of view.